Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians: Pilot Study

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03068156

Enrollment

Registered

2017-03-01

Start date

2022-01-31

Completion date

2023-03-02

Last updated

2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lichen Amyloidosis

Keywords

308-nm excimer laser, primary localized cutaneous amyloidosis, lichen amyloidosis, Asians

Brief summary

Efficacy of 308-nm excimer laser for primary localized cutaneous amyloidosis treatment in Asians, pilot study.

Interventions

RADIATION308-nm excimer laser

monochromator UVB laser (308nm)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients, aged \>18 years old with lichen amyloidosis diagnosed by using clinical presentation and pathologic features

Exclusion criteria

* Those with cutaneous amyloidosis associated systemic diseases * Pregnancy or lactating woman * Those who are allergic to urea, olive oil * Those who are photosensitive to ultraviolet radiation * Those who had been previously treated with medications/ radiation/ laser within 3 months for systemic and 1 month for topical therapy

Design outcomes

Primary

Measure	Time frame	Description
Roughness evaluation by using Visioscan® VC98	Change from baseline roughness at every 2 weeks up to 16 weeks	The improvement of roughness evaluation

Countries

Thailand

Contacts

PRINCIPAL_INVESTIGATOREinapak Amnarttrakul, M.D.

Chulalongkorn University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026